In comparison to Aβ42 levels, studies have consistently found increased CSF t-tau and p-tau levels in AD patients compared to normal controls (See [7] and [4] for meta-review and meta-analyses respectively). The gene discussed is MAPT; the disease is Alzheimer disease.